Always check for any changes in color or clarity, as this can indicate degradation
10.1038/s41598-022-12578-7 399 ShinN.-R.WhonT
Manufacturers may invest more heavily in next-generation obesity and diabetes therapies that offer improved convenience, stronger efficacy, or fewer gastrointestinal side effects
Who Might Consider BPC-157 and Who Should Avoid It Based on the preclinical data and clinical patterns of use, the patient populations most commonly prescribed BPC-157 for GI indications include: patients with persistent NSAID gastropathy despite PPI therapy, patients with functional GI symptoms attributed to intestinal barrier dysfunction, and patients with inflammatory bowel disease who have not responded adequately to biologic therapy and seek adjunctive options
(2015) 'Randomised, Placebo-Controlled Trial of Methyl B12 for Children with Autism', *Journal of Autism and Developmental Disorders*
Hoppe C, Molgaard C, Michaelsen KF: Cow's milk and linear growth in industrialized and developing countries